LY-364947

DESCRIPTION

LY-364947 is a selective inhibitor of transforming growth factor beta pathway and suppresses TGF-Beta dependent growth in the relevant cell lines. It is also reported to inhibit MDA-MB-231 breast cancer cells in a matrigel invasion assay and block chondrogenesis in human stem cells.

DETAILS

Purity: ≥98%
Synonyms: TbetaR-I Inhibitor, LY364947, LY 364947, Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor
Cas Number: 396129-53-6
References: S Bansal, S., Celia, C., Ferrati, S., Zabre, E., Ferrari, M., Palapattu, G., & Grattoni, A. (2013). Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations. Current drug targets,14(9), 1061-1069. Nassar, K., Tura, A., Lueke, J., Lueke, M., & Grisanti, S. (2012). The novel use of LY364947 (LY), a TGF-ß Type I receptor inhibitor, in prevention of proliferative vitreoretinopathy (PVR). Investigative Ophthalmology & Visual Science, 53(14), 893-893. Oka, M., Iwata, C., Suzuki, H. I., Kiyono, K., Morishita, Y., Watabe, T., ... & Miyazono, K. (2008). Inhibition of endogenous TGF-β signaling enhances lymphangiogenesis. Blood, 111(9), 4571-4579.
Application: FA
Formulation: Crystalline solid
Chemical Name: 4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
Molecular Weight: 272.3
Molecular Formula: C17H12N4
Storage Conditions: Product should be kept at -20°C.
Pubchem Openeye Can Smiles: C1=CC=C2C(=C1)C(=CC=N2)C3=C(NN=C3)C4=CC=CC=N4